Soligenix awards 78,947 stock options to director
A Soligenix director received a new 78,947-share stock option grant at a $0.38 exercise price, vesting through 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
SOLIGENIX, INC. (SNGX) reported that director Jerome B. Zeldis received a grant of stock options covering 78,947 shares of common stock on September 17, 2026. The options have an exercise price of $0.38 per share, expire on June 16, 2036, and vest in four equal installments from December 17, 2026 through September 17, 2027. No Rule 10b5-1 trading plan is reported for this grant.
Insider Trade Summary
Grant/Award: 78,947 shares
Grant/Award
1 txn
Insider
ZELDIS JEROME B
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 78,947 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 78,947 contracts (Direct)
Footnotes (1)
- F1. The stock option vests ratably on each of December 17, 2026, March 17, 2027, June 17, 2027 and September 17, 2027.
Key Figures
Stock options granted: 78,947 options
Exercise price: $0.38 per share
Underlying common shares: 78,947 shares
+3 more
6 metrics
Stock options granted
78,947 options
Director award on September 17, 2026
Exercise price
$0.38 per share
Exercise price for the 78,947-share option grant
Underlying common shares
78,947 shares
Shares of Soligenix common stock underlying the option grant
Options held after transaction
78,947 options
Total derivative securities held by the director following the award
Number of vesting installments
4 installments
Equal vesting on December 17, 2026; March 17, 2027; June 17, 2027; September 17, 2027
Option expiration date
June 16, 2036
Expiration date of the director’s 78,947-share option grant
Key Terms
Stock Option (Right to Buy), Common Stock, exercise price
3 terms
Stock Option (Right to Buy) financial
"Title of derivative security: Stock Option (Right to Buy)"
Common Stock financial
"Underlying security title is reported as Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"The options have an exercise price of $0.38 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did SOLIGENIX, INC. (SNGX) report for Jerome B. Zeldis?
Jerome B. Zeldis, a director of SOLIGENIX, INC. (SNGX), received a grant of stock options for 78,947 shares of common stock on September 17, 2026. This is an option award, not an open-market purchase or sale.
What is the exercise price of the new SNGX stock options granted to the director?
The stock options granted to the director have an exercise price of $0.38 per share. This is the price at which the option holder may buy Soligenix common stock upon exercising the options, subject to vesting and before expiration.
When do the newly granted SNGX stock options vest for the director?
The 78,947-share stock option grant vests ratably on four dates: December 17, 2026, March 17, 2027, June 17, 2027, and September 17, 2027. Each date represents an equal portion of the options becoming exercisable.
When do the reported SNGX stock options granted to the director expire?
The stock options granted to the director expire on June 16, 2036. After this expiration date, any unexercised options from this 78,947-share grant will no longer be exercisable.
How many derivative securities does the SNGX director hold after this transaction?
Following the grant, the director holds 78,947 stock options related to Soligenix common stock as reported in this Form 4. These options correspond to an underlying 78,947 shares of common stock if fully vested and exercised.
Were the SNGX director’s option grants made under a Rule 10b5-1 trading plan?
No. The report indicates that no Rule 10b5-1 trading plan is associated with this transaction. The grant is reported as a stock option award without reference to any pre-arranged trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
